---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-041169"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2026-02-06T23:59:59+00:00"
generated_at: "2026-05-16T04:07:32.516631+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology CEO Dr. Lara Sullivan steps down; board member Tom Civik appointed interim CEO

## Summary
- Effective February 2, 2026, Dr. Lara Sullivan stepped down as President, CEO, and CMO of Pyxis Oncology.
- Board appointed Thomas Civik, a current director, as Interim CEO; base salary $710K, target bonus 60%.
- Civik receives initial option grant (1.1% of shares) vesting monthly over 12 months, plus top-up (0.4%) upon successful transaction.
- Board launched search for permanent CEO; Civik previously led Five Prime through its $1.9B acquisition by Amgen.
- Lead program MICVO continues Phase 1/2 trials for head and neck squamous cell carcinoma; clinical operations unchanged.

## SEC filing metadata
- accession: 0001193125-26-041169
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2026-02-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000119312526041169/0001193125-26-041169-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000119312526041169/pyxs-20260206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-041169
- JSON: https://secwatch.observer/filing/0001193125-26-041169.json
- Plain text: https://secwatch.observer/filing/0001193125-26-041169.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.